The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A Phase 2 biomarker-enriched study of evofosfamide (TH-302) in patients with advanced melanoma.
 
Elaine McWhirter
No Relationships to Disclose
 
Omid Hamid
No Relationships to Disclose
 
Bartosz Chmielowski
Honoraria - Amgen; Merck
Consulting or Advisory Role - Amgen (Inst); Astellas Pharma (Inst); Genentech (Inst); Lilly (Inst); Merck/Schering Plough (Inst)
Speakers' Bureau - Bristol-Myers Squibb; Genentech/Roche
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Genentech/Roche; Lilly; Merck
 
Richard D. Carvajal
No Relationships to Disclose
 
David A. Jaffray
No Relationships to Disclose
 
Brandon Driscoll
No Relationships to Disclose
 
Tina Shek
No Relationships to Disclose
 
Ivan Yeung
No Relationships to Disclose
 
Harald Keller
No Relationships to Disclose
 
Trevor D. McKee
No Relationships to Disclose
 
Tillman E. Pearce
Employment - Threshold Pharmaceuticals
Stock and Other Ownership Interests - Threshold Pharmaceuticals
Travel, Accommodations, Expenses - Threshold Pharmaceuticals
 
Stew Kroll
Employment - Threshold Pharmaceuticals
Stock and Other Ownership Interests - Threshold Pharmaceuticals
Travel, Accommodations, Expenses - Threshold Pharmaceuticals
 
Anthony M. Joshua
Research Funding - Astellas Pharma; Janssen